> Return to News Page



Cardinal Health Obtains 510(k) Clearance for Victoreen® THEBES® II Therapy Beam Evaluation System

CLEVELAND, Ohio (April 7, 2003) — The Radiation Management Services business of Cardinal Health announced today that it has received Food and Drug Administration 510(k) clearance for its new THEBES II Therapy Beam Evaluation System. THEBES II now provides an effective means of dose verification.

Uniquely designed, THEBES II incorporates 47 ion chambers in a waterproof test instrument. Ion chambers eliminate the problems associated with older diode designs that are less accurate and subject to failure from radiation damage.

E. Ishmael Parsai, Ph.D, DABMP, Associate Professor and Chief of Medical Physics, Medical College of Ohio states: “My experience with the new THEBES II in commissioning the new multi-leaf collimator has been exciting. This new device, either attached to the head of the gantry for dynamic wedge and IMRT dose verification, or on the patient coach for morning QA, is an effective tool for physicists and is proven to be accurate and easy to use.”

Companion THEBES II Contour Manager software is also available and provides powerful information management, using Microsoft® Access with an SQL Server compatible database. The Contour Manager includes status bars, dockable toolbars, dockable Windows® to customize user screens, as well as capabilities to profile, compare, overlay, calculate percent depth dose and perform trend analyses.

About Radiation Management Services

The Radiation Management Services business of Cardinal Health is the industry leader in providing solutions for maintaining a safe, regulatory-compliant facility in the medical imaging and therapy fields and the nuclear power industry. Radiation detection instruments and information management software under the famous Victoreen brand are recognized worldwide.

About Cardinal Health

Cardinal Health, Inc. (www.cardinal.com) is the leading provider of products and services supporting the health care industry. Cardinal Health companies develop, manufacture, package and market products for patient care; develop drug-delivery technologies; distribute pharmaceuticals, medical-surgical and laboratory supplies; and offer consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 50,000 people on five continents and produces annual revenues of more than $47 billion. Cardinal Health is ranked #19 on the current Fortune 500 list and was named one of “The World’s Best” companies by Forbes magazine in 2002.

Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 8-K and Form 10-Q reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the costs, difficulties, and uncertainties related to the integration of acquired businesses, the loss of one or more key customer or supplier relationships, changes in the distribution patterns or reimbursement rates for health-care products and/or services, the costs and other effects of governmental regulation and legal and administrative proceedings, and general economic and market conditions. Cardinal Health undertakes no obligation to update or revise any forward-looking statements.

> Return to News Page

 
Contact Us Product Safety Legal Privacy Policy Site Index Search Home